Albert Wiegman Articles
Keynote: Clinical utility of cIMT in determining management of children with heFH and of CTCA in determining treatment effects in children with hoFH
Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board Albert Wiegman
read more »
Paediatric familial hypercholesterolaemia attracts new focus
Dr Albert Wiegman, Amsterdam University Medical Center, The Netherlands discusses the latest findings that have highlighted familial hypercholesterolaemia in children. For the second time within 12 months, a study about children with familial hypercholesterolaemia (FH, inherited high cholesterol) is published in The New England Journal…
read more »
Optimal treatment in children with FH urgently needed!
Familial hypercholesterolaemia (FH, inherited high cholesterol) is the most common inherited cause of premature coronary heart disease, affecting about 1 in 200-250 people (1). This means that worldwide, one baby is born with FH every minute. Therefore, diagnosing children with FH earlier, so that lifestyle…
read more »
Safety of lowering LDL-C
Dr Albert Wiegman discusses the safety of lowering LDL C in FH children
read more »
ISA 2015: EAS Consensus Panel publishes Position Statement on Paediatric Familial Hypercholesterolaemia
The European Atherosclerosis Society (EAS) Consensus Panel has today published a new position paper aiming to raise awareness of the urgent need to identify and treat children with familial hypercholesterolaemia (FH) early. The EAS Consensus Panel position paper also provides clinical guidance for the diagnosis…
read more »
Why is it critical to target children with FH?
Familial hypercholesterolaemia (FH) is the most common genetic disorder in the world. People with FH have high levels of low density lipoprotein cholesterol (LDL-C) resulting in a high risk of premature and sudden death. Now early diagnosis and treatment can save lives, says Dr Albert…
read more »
